

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 25 avril 2023 16:07

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Glanders and Melioidosis
Address of laboratory:	14 rue Pierre et Marie Curie
Tel.:	+33149771300
E-mail address:	karine.laroucau@anses.fr
Website:	https://www.anses.fr/fr
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Pascal BOIREAU
Name (including Title and Position) of WOA Reference Expert:	Dr Karine LAROUCAU
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT	yes	477	135
ELISA	yes	455	36
Direct diagnostic tests		Nationally	Internationally

PCR	yes	0	31
-----	-----	---	----

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHP?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHP Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHP Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHP Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAHP Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHP Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAHP MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Establishment of a standard serum	2 years	To have a standard serum for CFT and ELISA harmonisation	University of Faisalabad FLI CVRL ICRAD	ANTIGUA AND BARBUDA ALGERIA

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

5

Brangsch, H., H. Singha, K. Laroucau, and M. Elschner. 2022. "Sequence-based detection and typing procedures for *Burkholderia mallei*: Assessment and prospects." *Front Vet Sci* 9: 1056996. <https://doi.org/10.3389/fvets.2022.1056996>.

Falcao, M. V. D., K. Laroucau, F. Vorimore, T. Deshayes, V. L. A. Santana, K. P. C. Silva, S. A. do Nascimento, R. S. de Castro, F. R. Araujo, and R. A. Mota. 2022. "Molecular characterization of *Burkholderia mallei* strains isolated from horses in Brazil (2014-2017)." *Infect Genet Evol* 99: 105250. <https://doi.org/10.1016/j.meegid.2022.105250>.

Health, Efsa Panel on Animal, Welfare, S. S. Nielsen, J. Alvarez, D. J. Bicut, P. Calistri, E. Canali, J. A. Drewe, B. Garin-Bastuji, J. L. Gonzales Rojas, C. G. Schmidt, M. Herskin, V. Michel, M. A. Miranda Chueca, B. Padalino, P. Pasquali, H. Spooler, K. Stahl, A. Velarde, A. Viltrop, C. Winckler, S. Gubbins, K. Laroucau, S. E. Antoniou, I. Aznar, A. Broglia, E. Lima, Y. Van der Stede, G. Zancanaro, and H. C. Roberts. 2022. "Assessment of the control measures of the category A diseases of Animal Health Law: *Burkholderia mallei* (Glanders)." *EFSA J* 20 (1): e07069. <https://doi.org/10.2903/j.efsa.2022.7069>.

Koirala, P., M. Maharjan, S. Manandhar, K. R. Pandey, T. Deshayes, G. Wang, M. Valvano, and K. Laroucau. 2022. "First glanders cases detected in Nepal underscore the need for surveillance and border controls." *BMC Vet Res*. 18 (1): 132.

Wagner, GE., A. Berner, M. Lipp, C. Kohler, K. Assig, S. Lichtenegger, M. Saqib, E. Müller, T. Trinh, AM. Gad, HH. Söffing, R. Ehrlich, K. Laroucau, and I. Steinmetz. 2022. "Protein microarray guided development of a highly sensitive and specific dipstick assay for glanders serodiagnostics." *J Clin Microbiol* in press.

b) International conferences:

0

c) National conferences:

2

Laroucau K. 2022. "La mélioiidose". CES Anses Santé animale et Bien-être animal. Visioconférence. 11/01/22

Laroucau K. 2022. "La mélioiidose, une maladie émergente". Académie vétérinaire, Séance académique, zoonoses émergentes. EnvA Maisons-Alfort. 01/12/22

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHP Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025		Attestation 1-2246 révision 22.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CFT	COFRAC
ELISA	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

B. mallei and B. pseudomallei are covered by the French regulation ANSM (Highly Pathogenic Microorganisms and Toxins)(biosafety and biosecurity) - Inspections. Work in level 3 confined areas under the supervision of a risk manager (safety and security).

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

	SCOPE	NAME(S) OF RELEVANT WOAHP REFERENCE
--	-------	-------------------------------------

TITLE OF THE PROJECT OR CONTRACT		LABORATORIES
Constitution of a reference serum for serology	To have a reference serum for CFT/ELISA standardisation	OMSA ref Lab in Iena (Germany, Dr M. Elschner) OMSA ref Lab in Dubai (UE/ Dr Wernery)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

No

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

No